The HOX transcript antisense RNA (HOTAIR) has been reported to be aberrantly expressed in ovarian cancer (OC). Abnormal high expression level of HOTAIR has been found to be associated with poor overall survival of OC patients. Yet, the role of HOTAIR in paclitaxel resistance of OC is unclear. This study aims to investigate the effect, as well as the mechanism of HOTAIR in promoting paclitaxel resistance of OC.
Ovarian cancer cell lines with down-regulated and up-regulated expression of HOTAIR were, respectively, established. The expression of HOTAIR was confirmed by qRT-PCR. The sensitivity of ovarian cancer cells to paclitaxel was detected by MTT assays, colony formation, EdU assays, flow cytometry, and in vivo experiments.
An increased expression level of HOTAIR was observed in ovarian cancer cell lines following treatment with paclitaxel. When the expression of HOTAIR was down-regulated, the proliferation of ovarian cancer cells was found to be inhibited, coupled with enhanced cell sensitivity to paclitaxel. Conversely, when the HOTAIR expression was up-regulated, an opposite effect was observed on the ovarian cancer cells. In addition, cell cycle arrest in G2/M phase was also shown to be accelerated upon HOTAIR suppression. Strikingly, our results also revealed that HOTAIR plays a regulatory role in the expression of checkpoint kinase 1 (CHEK1), and that the restored paclitaxel sensitivity through knockdown of HOTAIR can be weakened by CHEK1 up-regulation. Consistently, in vivo data confirmed that the therapeutic efficacy of paclitaxel can be enhanced through down-regulation of HOTAIR, and that CHEK1 is the down-stream target of HOTAIR in inducing paclitaxel resistance.
HOTAIR confers paclitaxel resistance in epithelial ovarian cancer by increasing the protein level of CHEK1.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Availability of data and materials
The datasets used and/or analyzed in this study are available from the corresponding author on reasonable request.
Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533–543
Cannistra SA (2006) Intraperitoneal chemotherapy comes of age. N Engl J Med 354(1):77–79
Young M, Plosker GL (2001) Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. Pharmacoeconomics 19(12):1227–1259
Woo CJ, Kingston RE (2007) HOTAIR lifts noncoding RNAs to new levels. Cell 129(7):1257–1259
Marchese FP, Huarte M (2014) Long non-coding RNAs and chromatin modifiers: their place in the epigenetic code. Epigenetics 9(1):21–26
Chang L, Guo R, Yuan Z et al (2018) LncRNA HOTAIR regulates CCND1 and CCND2 expression by sponging miR-206 in ovarian cancer. Cell Physiol Biochem 49(4):1289–1303
Tang Q, Hann SS (2018) HOTAIR: an oncogenic long non-coding RNA in human cancer. Cell Physiol Biochem 47(3):893–913
Wu Y, Xiong Q, Li S et al (2018) Integrated proteomic and transcriptomic analysis reveals long noncoding RNA HOX transcript antisense intergenic RNA (HOTAIR) promotes hepatocellular carcinoma cell proliferation by regulating opioid growth factor receptor (OGFr). Mol Cell Proteomics 17(1):146–159
Cheng C, Qin Y, Zhi Q et al (2018) Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/beta-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol 107(Pt B):2620–2629
Ozes AR, Miller DF, Ozes ON et al (2016) NF-kappaB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene 35(41):5350–5361
Yu Y, Zhang X, Tian H, Zhang Z, Tian Y (2018) Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy. J BUON 23(5):1396–1401
Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ (2009) Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 69:3918–3926
Zhang SF, Wang XY, Fu ZQ, Peng QH, Zhang JY, Ye F, Fu YF, Zhou CY, Lu WG, Cheng XD, Xie X (2015) TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer. Autophagy 11(2):225–238
Fu Y, Ye D, Chen H, Lu W, Ye F, Xie X (2007) Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol Oncol 105:66–73
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25(4):402–408
Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123:725–731
Xiao Z, Xue J, Semizarov D et al (2005) Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int J Cancer 115(4):528–538
Kim A, Ueda Y, Naka T et al (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31:14
McGuire WP, Hoskins WJ, Brady MF et al (1997) Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol 24(1 Suppl 2):S2-13–S2-16
Xue X, Yang YA, Zhang A et al (2016) LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 35(21):2746–2755
Wang H, Li Q, Tang S et al (2017) The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. Hematology 22(4):208–216
Zhou Y, Wang C, Liu X et al (2017) Long non-coding RNA HOTAIR enhances radioresistance in MDA-MB231 breast cancer cells. Oncol Lett 13(3):1143–1148
Jing L, Yuan W, Ruofan D et al (2015) HOTAIR enhanced aggressive biological behaviors and induced radio-resistance via inhibiting p21 in cervical cancer. Tumour Biol 36(5):3611–3619
Abdeahad H, Avan A, Pashirzad M et al (2019) The prognostic potential of long noncoding RNA HOTAIR expression in human digestive system carcinomas: a meta-analysis. J Cell Physiol 234(7):10926–10933
Cui L, Xie XY, Wang H et al (2013) Expression of long non-coding RNA HOTAIR mRNA in ovarian cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 44(1):57–59
Chi S, Liu Y, Zhou X et al (2019) Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B. Cancer Chemother Pharmacol 83(2):277–287
Wang H, Qin R, Guan A, Yao Y, Huang Y, Jia H, Huang W, Gao J (2018) HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression. J Cell Biochem 119(9):7226–7234
Goto H, Izawa I, Li P et al (2012) Novel regulation of checkpoint kinase 1: is checkpoint kinase 1 a good candidate for anti-cancer therapy? Cancer Sci 103(7):1195–1200
Zhang XZ, Liu H, Chen SR (2020) Mechanisms of long non-coding RNAs in cancers and their dynamic regulations. Cancers (Basel) 12(5):1245
Zhao H, Wang A, Zhang Z (2020) LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465. J Biochem. https://doi.org/10.1093/jb/mvaa036
Xu M, Zhou K, Wu Y, Wang L, Lu S (2019) Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1. Mol Carcinog 58(4):577–587
Wang J, Ye C, Liu J, Hu Y (2018) UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochem Biophys Res Commun 501(4):1034–1040
This work was supported by the National Natural Science Foundation of China (No. 81602277) and the Natural Science Foundation of Hubei Province (No. 2018CFB557).
Conflict of interest
The authors declare no conflicts of interest.
Appropriate approvals were obtained.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jiang, J., Wang, S., Wang, Z. et al. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer. Cancer Chemother Pharmacol (2020). https://doi.org/10.1007/s00280-020-04120-1
- Drug resistance
- Ovarian cancer